Led · Series B · Jul 2024

Clarapath develops robotics, machine vision and digital automation tools to modernize how pathology laboratories process tissue, with its SectionStar system positioned as an all‑in‑one tissue sectioning and transfer solution. SectionStar is described as the first (pending U.S. launch) system that increases capacity, reliability and consistency while reducing the need for highly skilled labor. The company says its automation captures and aggregates new data to improve downstream digital pathology and diagnostic review. Clarapath cites a strained laboratory environment driven by severe labor shortages, rising caseloads and antiquated manual workflows as rationale for its products; the article notes more than 12 million human and veterinary biopsies are performed annually in the U.S. The company operates medical device development in Hawthorne, NY and runs a CLIA‑certified laboratory serving clinical and non‑clinical organizations. With this financing, Clarapath plans to accelerate commercialization of SectionStar and expand sales, service, precision manufacturing and R&D to build an end‑to‑end 'lab of the future.' Clarapath develops SectionStar, a fully automated, all‑in‑one tissue sectioning and transfer system that standardizes and accelerates the preparation of glass slides for pathology. SectionStar consolidates manual cutting, quality control, and decision steps to produce more consistent tissue sections and support AI‑driven analysis. The company says the system increases throughput, reduces reliance on skilled labor, and generates richer datasets for molecular mapping and precision‑medicine research. Clarapath works with research and clinical customers today, including Northwell Health and The Ellison Institute, and operates a CLIA‑certified clinical research organization that offers whole slide imaging and automated image processing. The company plans to launch SectionStar first in the non‑clinical market in the near term while targeting the larger clinical market as its ultimate goal. Recent financing will support product development, team growth, and expanded sales and service efforts.

Participated · Series B · Mar 2024

Hume AI builds AI systems that integrate advances in artificial intelligence, human behavior research, and health to create tools optimized for human well-being. Its core offerings include an advanced API toolkit for measuring human emotional expression and a newly released beta of its flagship Empathic Voice Interface (EVI) that developers can embed with a single API call. EVI is powered by a multimodal "empathic large language model" (eLLM) that integrates LLMs with expression measures to adapt words and tone based on users' emotional expressions and conversational context. The company says EVI was trained on data from millions of human interactions and can detect turn endings, stop when interrupted, and generate responses with latency under 700 ms for fluid, near‑human conversation. Hume's toolkit is already used across industries including robotics, customer service, healthcare, wellness, and user research, and the company cites collaborations with Softbank, Lawyer.com, Harvard, and Mt. Sinai. The team comprises about 35 researchers, engineers, and scientists led by founder Dr. Alan Cowen, and Hume supports a nonprofit, The Hume Initiative, which has released ethical guidelines for empathic AI. Hume AI develops models and datasets that analyze speech prosody, vocal bursts, facial expressions, and language to characterize human emotion. The company exposes its datasets and models through a unified API platform. Since its public launch in January 2021, Hume AI has been tripling its revenue growth quarter over quarter. It began rolling out a beta to a waitlist of more than two thousand companies and research organizations, with an early focus on healthcare applications. Hume AI has research partnerships with labs at Mt. Sinai, Boston University Medical Center, and Harvard Medical School to study clinical uses such as screening, triage, diagnosis, patient monitoring, and crisis prediction. The company is led by founder and CEO Dr. Alan Cowen, an expert in affective science. Hume AI develops machine learning models and natural language understanding tools that capture vocal tone, rhythm and nonverbal signals (sighs, gasps, laughs) rather than relying solely on speech-to-text transcripts. The company’s website says its models outperform NLU approaches that convert speech into text by accounting for prosody and subtle expressive cues. Hume’s research-led team is led by emotion scientist Alan Cowen, a former researcher at Google and UC Berkeley, and the startup trained models on data collected around the world to characterize expressive communication across cultures. That global training is cited as helping reduce bias and improve accuracy across diverse ages and demographic groups. Hume positions its technology for clinical use cases such as assessing pain, depression and cognitive impairment. Northwell will collaborate with Hume’s team to validate the technology in clinical settings and explore high-impact applications across its enterprise.

Participated · Equity · Apr 2023

Memora Health is a San Francisco-based provider of an intelligent care enablement platform. Its system digitizes and automates clinical workflows, charging care teams by intelligently triaging patient-reported concerns and data to appropriate care team members and providing patients with proactive, two-way communication and support. The platform helps clinicians focus on practice while proactively engaging patients along complex care journeys. Memora partners with health systems, health plans, and digital health companies. Led by CEO Manav Sevak, the company intends to use the funds to expand operations and its business reach. Memora Health is a San Francisco-based technology platform that helps healthcare organizations digitize and automate care journeys for virtual care delivery and complex care management. It ingests existing clinical workflow data and converts it into cohesive messaging journeys that guide patients through care episodes and automates completion of simple follow-up tasks in the EHR. The platform integrates with EHRs, CRMs, and existing clinical and administrative workflows and trains AI on the clinical data generated during routine care. Memora has digitized clinical workflows with partners including the Mayo Clinic, Edward Elmhurst Health and Penn Medicine, supporting use cases from automated closing of care gaps to intelligent remote monitoring and proactive care coordination. Led by CEO Manav Sevak, the company plans to use the $40M financing to accelerate growth and expand operations and its business reach. Memora Health builds a proprietary, machine-learning driven platform that converts fragmented healthcare messaging and workflow data into smart modules to enable more continuous care delivery. The system integrates with electronic medical record and patient management systems to change how existing tools are used and to automate collection of rich, actionable clinical data outside episodic visits. Its platform supports patient communication, symptom triage, remote monitoring, evidence-based pathways, clinical documentation, and reimbursement workflows, aiming to create an always-learning health system around modern care delivery. The company has partnered with over 55 healthcare organizations, including the Mayo Clinic, Penn Medicine, Banner Health, and Dana Farber Cancer Institute. Led by CEO and co-founder Manav Sevak, Memora intends to use new funding to expand operations and broaden its business reach. The company is headquartered in San Francisco, CA. Memora Health offers Felix, an SMS-based virtual assistant that automates post-discharge follow-ups and reminders (medication, prescriptions, glucose/weight checks) by accessing patients' electronic medical records and using a HIPAA-compliant SMS service. The platform onboards patients when they leave a hospital or care center and is free to patients; three hospitals and 10 private practices pay Memora Health a fee plus a per-patient cost. The company says it currently has more than 1,500 patients using its service across chronic disease and post-surgery care. Memora positions Felix as efficiency/optimization software rather than a chatbot and emphasizes automating existing follow-up workflows. Memora launched out of stealth and is graduating from Y Combinator’s Winter 2018 batch. The company was founded in June 2016 and had six employees at the time of the article.

Participated · Equity · Apr 2023

Neuvotion develops NeuStim™, a technology that combines highly targeted neurostimulation with artificial intelligence to accelerate rehabilitation and make physical and occupational therapy more effective. The company focuses on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Neuvotion plans a multi-site clinical study to begin this year and intends to complete clinical studies using the new funding. Management says it will use the funds to expand its team and pursue FDA clearance for its initial product. Founded by Chad Bouton and based in Darien, CT, Neuvotion is in the early-stage clinical and regulatory phase. The company recently raised additional capital that brings its total funding to $2.75M. Neuvotion is an early-stage medical device company focused on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Its core product, NeuStim™, combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. The company is led by founder and CEO Chad Bouton and is based in Darien, CT. Neuvotion has received an exclusive worldwide license from Northwell Health for its technology. It raised over $1M in seed funding to advance development and clinical validation, and plans to use the proceeds to expand its team, conduct a multi-site clinical study next year, and pursue FDA clearance for its initial product.

Participated · Seed · Aug 2022

Violet provides a cultural competence credentialing and upskilling platform for clinicians that uses a proprietary framework to measure clinicians' cultural competence. The company uses that measurement data to build personal upskilling pathways and to power identity-centered care coordination for patients. Since its founding in 2020, Violet has enabled customers including Brightline, Galileo, Parsley Health, Headway, Octave, and NOCD to launch identity-centered care. Led by CEO Gaurang Choksi, the company plans to use new capital to expand its credentialing reach, build inclusivity training, and power more care coordination. Financially, Violet raised a $4.1M Seed round that brought total funding to date to $5.3M.